This month on pharmaphorum, we explore the history of French pharmaceutical company Sanofi, which was created through many partnerships and acquisitions over a period of 100 years. Sanofi is one ...

17 story has been corrected to say the results were for ulcerative colitis, not for both the diseases, in paragraph 5) Teva and Sanofi said last year they would collaborate on developing a ...

Sanofi has officially opened a modular biologics manufacturing facility in Singapore that is designed to allow rapid switching between products and could be used to respond to an emerging pandemic ...

Sanofi, a leader in immunology, had said it will invest $1.5 billion in the development of Teva's anti-TL1A drug undergoing phase 2 trials. U.S.-listed shares of Teva and Sanofi rose 19% and 4% ...

The trial outcome could represent the “next frontier” in UC and CD treatment, Sanofi’s head of research and development, Houman Ashrafian, M.D., Ph.D., said in a statement.

Gilead Sciences has raided Sanofi for its next chief medical officer, luring Dietmar Berger, M.D., Ph.D., away from the French drugmaker to replace Merdad Parsey, M.D ...

Sanofi unveiled a plan to build a $1 billion manufacturing site in Beijing while completing construction at a plant in Singapore. GSK inked an antibody-drug conjugate deal with DualityBio and ...

The primary endpoint, durable platelet response was observed in 23% of the therapy-treated adults. Credit: Volha_R/Shutterstock. Sanofi has reported that the Phase III LUNA 3 trial of rilzabrutinib ...

SAR-441566 is under clinical development by Sanofi and currently in Phase II for Rheumatoid Arthritis. According to GlobalData, Phase II drugs for Rheumatoid Arthritis have a 35% phase transition ...

SAR-442970 is under clinical development by Sanofi and currently in Phase II for Hidradenitis Suppurativa. According to GlobalData, Phase II drugs for Hidradenitis Suppurativa have a 44% phase ...